๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Marketing and drug costs: Who is laughing and crying?

โœ Scribed by S. Claiborne Johnston; Stephen L. Hauser


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
40 KB
Volume
61
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Drug development costs when financial ri
โœ John A. Vernon; Joseph H. Golec; Joseph A. Dimasi ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 69 KB

## Abstract In a widely cited article, DiMasi, Hansen, and Grabowski (2003) estimate the average preโ€tax cost of bringing a new molecular entity to market. Their base case estimate, excluding postโ€marketing studies, was $802 million (in $US 2000). Strikingly, almost half of this cost (or $399 milli

Identifying who is at risk of drug-induc
โœ Shivakumar Chitturi; Geoffrey C. Farrell ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 237 KB

In the classical form of alpha1-antitrypsin (AT) deficiency, a point mutation in AT alters the folding of a liver-derived secretory glycoprotein and renders it aggregation-prone. In addition to decreased serum concentrations of AT, the disorder is characterized by accumulation of the mutant alpha1-a

Acute and Chronic Toxicity of Veratrum V
โœ Perdue, Adoline S. ;Bell, Frances ;Starnes, W.R. ;Hitchcock, Philip ;Teague, R.S ๐Ÿ“‚ Article ๐Ÿ“… 1950 ๐Ÿ› Elsevier โš– 346 KB ๐Ÿ‘ 1 views